Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THR-317 plus ranibizumab for diabetic macular oedema
2017-003897-15Phase 2Completed
- Sponsor
- Oxurion
- Start
- Dec 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of THR-317 in diabetic macular edema (DME) (2 arms), sponsored by Oxurion. Primary endpoint: Change from baseline in BCVA. Started Dec 2017; status: completed.
02
Drugs
THR-317
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on 2017-003897-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003897-15.